prostate cancer

Researchers from the Cancer Genetics Group at IPO Porto, in collaboration with the School of Medicine and Biomedical Sciences at the University of Porto (ICBAS), have uncovered a key singaling pathway driving the aggressiveness of prostate tumors that overexpress ETV1. The team found that simultaneous activation of the EGFR and STAT3 signaling pathways fuels the malignant behavior of these cancers.

Investigadores do Grupo de Oncogenética do IPO Porto, em colaboração com o Instituto de Ciências Biomédicas Abel Salazar da Univerisdade do Porto (ICBAS), identificaram uma via de sinalização que impulsiona a agressividade de carcinomas da próstata com sobre-expressão de ETV1. A equipa de investigação descobriu que a activação das vias EGFR e STAT3 promove o comportamento maligno destes carcinomas.

17 February, 2025

Join here: https://uofglasgow.zoom.us/j/84392496282?pwd=5kSqAXNoAijjPS1XlV79sE0gJwXbIt.1 (Meeting ID: 843 9249 6282; Pass code: 622116).

17 February, 2025

Join here: https://uofglasgow.zoom.us/j/84392496282?pwd=5kSqAXNoAijjPS1XlV79sE0gJwXbIt.1 (Meeting ID: 843 9249 6282; Pass code: 622116).

Researchers from the Molecular Oncology and Viral Pathology Group (GOMPV) at the Research Center of IPO-Porto (CI-IPOP), in collaboration with researchers from Instituto de Investigação e Inovação em Saúde (i3S), established a 3D in vitro model of castration-resistant prostate cancer, applicable for identifying extracellular vesicle (EV)-derived microRNAs predictive of enzalutamide (ENZ) resistance development.

Study shows that diosgenin, a phytosteroid sapogenin, suppresses viability and promotes apoptosis of human prostate cancer cells with effects enhanced by the activation of the G protein-coupled estrogen receptor activation. 

Authors and Affiliations:

Marília I. Figueira¹, Ricardo Marques², Henrique J. Cardoso¹, Lara R. S. Fonseca¹, Ana P. Duarte¹, Samuel Silvestre¹ and Sílvia Socorro¹

Estudo mostra que a diosgenina, uma sapogenina fitoesteróide, suprime a viabilidade e promove a apoptose de células cancerígenas da próstata humana com efeitos potenciados pela ativação do recetor de estrogénios acoplado à proteína G.

Autores e afiliações:

Marília I. Figueira¹, Ricardo Marques², Henrique J. Cardoso¹, Lara R. S. Fonseca¹, Ana P. Duarte¹, Samuel Silvestre¹ and Sílvia Socorro¹

Pathologists demonstrate that GATA3 may be expressed in metastatic adenocarcinoma of the prostate, constituting an important diagnostic pitfall.

Authors and affiliations
João Lobo ^{1 2 3}, Nazario P Tenace ⁴, Sofia Cañete-Portillo ⁵, Isa Carneiro ^{1 2}, Rui Henrique ^{1 2 3}, Roberta Lucianò ⁴, Lara R Harik ⁶, Cristina Magi-Galluzzi ⁵

Researchers from the Cancer Biology & Epigenetics Group at the Research Center of IPO Porto, Portugal have revealed a pivotal link between epigenetic regulation and prostate cancer radioresistance. The study, entitled "Epigenetic Regulation of TP53 is Involved in Prostate Cancer Radioresistance and DNA Damage Response Signaling," was recently published in the prestigious journal Signal Transduction and Targeted Therapy.